Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Assets Current | |||||||||||
Cash And Cash Equivalents At Carrying Value | 74 | 62 | 47 | 39 | 26 | 27 | |||||
Short Term Investments | 0 | 29 | 63 | 87 | 116 | 125 | |||||
Prepaid Expense And Other Assets Current | 7 | 2 | 2 | 3 | 3 | 3 | |||||
Assets Current | 81 | 94 | 112 | 129 | 145 | 155 | |||||
Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 1 | 1 | |||||
Other Assets Noncurrent | 0 | 5 | 5 | 4 | 2 | 2 | |||||
Assets | 81 | 99 | 117 | 133 | 147 | 157 | |||||
Liabilities And Stockhold… | |||||||||||
Liabilities | |||||||||||
Accounts Payable Current | 2 | 4 | 2 | 4 | 5 | 3 | |||||
Accrued Liabilities Current | 4 | 7 | 8 | 6 | 5 | 3 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | 6 | 12 | 11 | 11 | 10 | 6 | |||||
Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | |||||
Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | |||||
Liabilities | 7 | 12 | 11 | 11 | 11 | 6 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 227 | 224 | 222 | 221 | 219 | 218 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 0 | 0 | 0 | 0 | -0 | 0 | |||||
Retained Earnings Accumulated Deficit | -152 | -138 | -116 | -98 | -82 | -68 | |||||
Stockholders Equity | 75 | 87 | 107 | 122 | 137 | 151 | |||||
Liabilities And Stockholders Equity | 81 | 99 | 117 | 133 | 147 | 157 | |||||
Temporary Equity Par Or Stated Value Per Share | - | - | 0 | 0 | 0 | 0 | |||||
Temporary Equity Shares Authorized | - | - | 0 | 0 | 0 | 0 | |||||
Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 0 | |||||
Temporary Equity Shares Outstanding | - | - | 0 | 0 | 0 | 0 | |||||
Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | |||||
Common Stock Shares Issued | 22 | 22 | 22 | 22 | 22 | 22 | |||||
Shares Outstanding | 22 | 22 | 22 | 22 | 22 | 22 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.61% | -14.46% | 12.86% | - | - | - | - | - | - | - | - | - |
| 2025 | 35.13% | 59.27% | 38.79% | -23.21% | 43.57% | -4.55% | 24.86% | 21.45% | 19.61% | 28.66% | 12.42% | -4.06% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Aardvark Therapeutics, Inc. (AARD) — SEC Financial Statements & Analysis
Aardvark Therapeutics, Inc. (AARD) is a pharmaceutical preparations company, incorporated in DE. Aardvark Therapeutics, Inc. trades on Nasdaq as: AARD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Aardvark Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 30.99x (TTM), a Price-to-Book (P/B) ratio of 1.68x (TTM), at a market cap of $125.83M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.09x
- P/S TTM
- 30.99x
- P/B TTM
- 1.68x
- Market Cap
- $125.83M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aardvark Therapeutics, Inc. in?
Aardvark Therapeutics, Inc. (AARD) operates in the Pharmaceutical Preparations industry.
What is AARD's market cap?
Aardvark Therapeutics, Inc. (AARD) has a market capitalization of $125.83M as of 2026-06-30.
What exchange does AARD trade on?
Aardvark Therapeutics, Inc. (AARD) trades on the Nasdaq.
Where is Aardvark Therapeutics, Inc. incorporated?
Aardvark Therapeutics, Inc. is incorporated in DE.